Related Experiment Video
Updated: Jul 10, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Atorvastatin in prevention of stroke and transient ischaemic attack
1Bichat University Hospital, Department of Neurology and Stroke Centre, 46 rue Henri Huchard, 75018 Paris, France. pierre.amarenco@bch.aphp.fr
Insights
Statins significantly reduce stroke and major coronary events in high-risk patients. Achieving a greater reduction in low-density lipoprotein cholesterol (LDL-C) with statins correlates with a lower risk of stroke.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- Statins are crucial in managing vascular risk, alongside blood pressure-lowering drugs and antithrombotics.
- They are particularly effective in secondary stroke prevention, reducing major coronary events.
- The SPARCL trial investigated atorvastatin's efficacy in patients with recent stroke or transient ischemic attack.
Purpose of the Study:
- To evaluate the effectiveness of high-dose atorvastatin (80 mg/day) in reducing stroke and major coronary events.
- To assess the impact of low-density lipoprotein cholesterol (LDL-C) reduction on stroke risk in secondary prevention.
- To determine if achieving a specific LDL-C target (<70 mg/dl) offers superior stroke prevention compared to standard statin doses.
Main Methods:
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial randomized patients with recent stroke/TIA to atorvastatin 80 mg/day or placebo.
- A post-hoc analysis utilized blinded LDL-C measurements to assess adherence and correlate LDL-C reduction with outcomes.
- Patients were categorized based on LDL-C changes: no change/increase vs. ≥50% reduction.
Main Results:
- Atorvastatin 80 mg/day significantly reduced stroke risk by 16% and major coronary events by 35% compared to placebo.
- Even with background statin use in the placebo arm, atorvastatin demonstrated significant benefits.
- A ≥50% reduction in LDL-C was associated with a significant 31% reduction in stroke risk compared to no LDL-C change or increase.
Conclusions:
- High-dose atorvastatin is effective in reducing stroke and major coronary events in patients with a history of stroke or TIA.
- The extent of LDL-C lowering is a key determinant of statin efficacy in stroke prevention.
- Further research is needed to compare intensive LDL-C lowering (<70 mg/dl) against standard statin therapy for secondary stroke prevention.
Abstract:
Besides blood pressure-lowering drugs and, in certain circumstances, antithrombotic agents, statins are among the most effective drugs in reducing the risk of stroke in populations of patients at high vascular risk, as well as the risk of major coronary events. In secondary prevention of stroke, statins clearly reduced the risk of major coronary events. In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, compared with placebo, the patients with a recent stroke or transient ischaemic attack without coronary heart disease randomised to atorvastatin 80 mg/day had a significant 16% relative risk reduction of stroke and a 35% reduction in the risk of major coronary events. This was obtained despite the fact that 25% of patients allocated to the placebo arm were prescribed a commercially available statin outside the trial. A post-hoc analysis used blinded low-density lipoprotein cholesterol (LDL-C) measurements (taken at study visits during the trial) as a marker of adherence to lipid-lowering therapy. Compared with the group with no change or an increase in LDL-C (the group adherent to placebo or not taking a statin), the group with >or= 50% reduction in LDL-C had a significant 31% reduction in the risk of stroke. The next step is to define whether or not achieving a LDL-C of < 70 mg/dl is better than a standard dose of statin (LDL approximately 100 - 110 mg/dl) in the secondary prevention of stroke. Statins are effective in reducing both first-ever and recurrent stroke, and this effect seems driven by the extent of LDL-C lowering.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:26Transient Ischemic Attack l: Introduction
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...